Cambridge Antibody Technology Group plc Company Profile

04:46 EDT 19th June 2018 | BioPortfolio

The foundation of CAT's business is its unique antibody technologies, which it continues to develop and exploit. Based on this, CAT has established a position as a world leader, exploiting the characteristics of antibodies both to discover and validate new disease targets and to develop human monoclonal antibodies as new treatments for disease.


The Science Park
United Kingdom


Phone: +44 (0) 1763 263 233
Fax: +44 (0) 1763 263 413

News Articles [1578 Associated News Articles listed on BioPortfolio]

New Rabbit Monclonal Antibody to Group B Streptococcus

New antibody reacts with the GBS Lancefield carbohydrate antigen found on the surface of the bacterium

Could a new antibody screening method lead to better drugs?

Antibody proteins have been the fastest-growing class of approved drugs over the last two decades, but current antibody drug discovery...Read More... The post Could a new antibody screening method lea...

Cambridge Analytica Suspends CEO After Alarming Reports On Its Election Maneuvers

Cambridge Analytica, the British political research group linked to President

Cullinan Oncology and MAB Discovery Collaborate on Novel Antibody Therapeutics

US Cullinan Oncology, based in Cambridge, MA, and German MAB Discovery (MABD) announced the initiation of a collaboration to develop novel antibody therapeutics based on MABD's discovery platform.

Predictive Technology Group to Acquire FlagshipHealth Group

Predictive Technology Group, Inc., a provider of data analytics for disease identification and subsequent therapeutic intervention through unique biotechnology treatments has finalized an arrangement ...

Academic Drug Discovery 2016 March 22-23 2016 Cambridge, UK

SELECTBIO is pleased to announce Academic Drug Discovery 2016, which will be held on 22 – 23 March 2016 in Cambridge, UK. The event is part of our Cambridge Workshop Series. Attracting a global ...

Eisai and Biogen’s Alzheimer’s Disease Drug Fails in Mid-Stage Trial

CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, Un...

Glythera Appoints Professor Kerry Chester to SAB

Appointment supports the development of the Company’s pipeline Glythera Limited (Glythera), the next-generation antibody drug conjugate (ADC) development company, today anno...

PubMed Articles [3798 Associated PubMed Articles listed on BioPortfolio]

Integration of Antibody Array Technology into Drug Discovery and Development.

Antibody arrays represent a high-throughput technique that enables the parallel detection of multiple proteins with minimal sample volume requirements. In recent years, antibody arrays have been widel...

Barcoded sequencing workflow for high throughput digitization of hybridoma antibody variable domain sequences.

Since the invention of Hybridoma technology by Milstein and Köhler in 1975, its application has greatly advanced the antibody discovery process. The technology enables both functional screening and l...

Immunological Effect of aGV Rabies Vaccine Administered Using the Essen and Zagreb Regimens: A Double-Blind, Randomized Clinical Trial.

This study evaluated the immunological effect of an aGV rabies virus strain using the Essen and Zagreb immunization programs. A total of 1,944 subjects were enrolled and divided into three groups: the...

Toward rational antibody design: recent advancements in molecular dynamics simulations.

Because antibodies have become an important therapeutic tool, rational antibody design is a challenging issue involving various science and technology fields. From the computational aspect, many types...

Stinging nettle and neem enhance antibody response to local killed and imported live infectious bursal disease vaccines in indigenous chicken in Kenya.

Immune responses are critical for protection of chickens from infectious bursal disease (IBD). In this study, the antibody response-enhancing effect of drinking water supplementation of 1% stinging ne...

Clinical Trials [6653 Associated Clinical Trials listed on BioPortfolio]

Analysis of Biopsies With Antibody Mediated Rejection According to the Therapy Response

In adult kidney transplant recipients a therapy-responder and non-responder phenotype by antibody mediated rejection will be precisely defined according to clinical and histological charac...

Feasibility Study Identifying Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Young Infants.

Feasibility phase for a study to evaluate antibody levels against Group B Streptococcus in mothers and their infants at delivery to establish antibody levels associated with reductions in ...

Study of the Effect of the VR Technology on Recovery of the Autonomic Nervous System in Volunteers Affected by Strees.

The study assess the effect of the VR technology (Pure Purr technology) on the recovery of the autonomic nervous system in healthy volunteers affected by moderate stress. Study subject ran...

A Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS Vaccine

This study looks at the body's immune responses to a GBS vaccine 2 years after the orginal vaccine(s) were given in the V98P1 study. Blood will be drawn and evaluated for GBS antibody lev...

The Application of Wearable Technology to Improve the Physical Activity Level of People With Chronic Mental Illness

The object is to develop a physical activity promotion program by applying social cognitive theory and wearable technology and evaluate its feasibility in people with MI Stage I: Accuracy...

Companies [3133 Associated Companies listed on BioPortfolio]

Cambridge Antibody Technology

Cambridge Antibody Technology (CAT) is a biopharmaceutical company committed to developing human monoclonal antibody therapeutics to bring improvements to seriously ill patients' lives.CAT has strong ...

Cambridge Antibody Technology Group plc

The foundation of CAT's business is its unique antibody technologies, which it continues to develop and exploit. Based on this, CAT has established a position as a world leader, exploiting the charact...

Domantis Inc

Domantis Limited was launched in December 2000 by Sir Gregory Winter and Dr Ian Tomlinson of the MRC–LMB with the backing of the MRC and MVM Limited to commercialise Domain Antibody products. To dat...

Granta Park Ltd

Granta Park has established itself as the leading research park in the Cambridge sub-region. Concentrating on the life sciences it has attracted many of the foremost businesses in the field, including...

The Cambridge Group

The Cambridge Group ( is a strategy consulting firm focused on the development of growth strategies for Fortune 500 companies. For over 30 years, The Cambridge Gr...

More Information about "Cambridge Antibody Technology Group plc" on BioPortfolio

We have published hundreds of Cambridge Antibody Technology Group plc news stories on BioPortfolio along with dozens of Cambridge Antibody Technology Group plc Clinical Trials and PubMed Articles about Cambridge Antibody Technology Group plc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cambridge Antibody Technology Group plc Companies in our database. You can also find out about relevant Cambridge Antibody Technology Group plc Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record